

## Derivation of new modality ‘Next Generation TPD’ leading materials targeting new target SOX2

EPD Biotherapeutics Inc.



ONCOLOGY	Lead
Product Type	Gene therapy (mRNA)
Indication	Lung cancers (Squamous Cell Lung Carcinoma, Squamous Cell Lung Carcinoma)
Target	SOX2 (Sex-determining region Y-box 2)
MoA(Mechanism of Action)	Targeted SOX2 degradation via UPS
Competitiveness	<p>1) Pre-existing protein degradation: In the case of siRNA, it is not possible to affect the existing SOX2 proteins already expressed before drug administration. However, EPD's EPDeg™ platform is expected to show faster and more effective treatment efficacy because it can degrade the existing SOX2 proteins immediately after drug administration.</p> <p>2) Undruggable target degradation: EPDeg™ platform is possible to degrade even most of the undruggable target proteins such as a transcription factors that can not be bonded with small molecule based PROTACs.</p>
Development Stage	Lead
Route of Administration	I.V.